BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 34649783)

  • 1. Extended venous thromboprophylaxis in patients hospitalized for acute ischemic stroke: A systematic review and meta-analysis.
    Valeriani E; Potere N; Candeloro M; Spoto S; Porreca E; Rutjes AW; Di Nisio M
    Eur J Intern Med; 2022 Jan; 95():80-86. PubMed ID: 34649783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study.
    Cohoon KP; De Sanctis Y; Haskell L; McBane RD; Spiro TE
    J Thromb Haemost; 2018 Jul; 16(7):1278-1287. PubMed ID: 29753308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended-duration versus short-duration pharmacological thromboprophylaxis in acutely Ill hospitalized medical patients: a systematic review and meta-analysis of randomized controlled trials.
    Liew AY; Piran S; Eikelboom JW; Douketis JD
    J Thromb Thrombolysis; 2017 Apr; 43(3):291-301. PubMed ID: 27900627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
    Chi G; Goldhaber SZ; Kittelson JM; Turpie AGG; Hernandez AF; Hull RD; Gold A; Curnutte JT; Cohen AT; Harrington RA; Gibson CM
    J Thromb Haemost; 2017 Oct; 15(10):1913-1922. PubMed ID: 28762617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis.
    Albertsen IE; Larsen TB; Rasmussen LH; Overvad TF; Lip GY
    Drugs; 2012 Sep; 72(13):1755-64. PubMed ID: 22876779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
    Di Nisio M; Porreca E; Candeloro M; De Tursi M; Russi I; Rutjes AW
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD008500. PubMed ID: 27906452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).
    Gibson CM; Chi G; Halaby R; Korjian S; Daaboul Y; Jain P; Arbetter D; Goldhaber SZ; Hull R; Hernandez AF; Gold A; Bandman O; Harrington RA; Cohen AT;
    Circulation; 2017 Feb; 135(7):648-655. PubMed ID: 27881569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis.
    Mahan CE; Burnett AE; Fletcher ML; Spyropoulos AC
    Hosp Pract (1995); 2018 Feb; 46(1):5-15. PubMed ID: 29171776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interventions for implementation of thromboprophylaxis in hospitalized medical and surgical patients at risk for venous thromboembolism.
    Kahn SR; Morrison DR; Cohen JM; Emed J; Tagalakis V; Roussin A; Geerts W
    Cochrane Database Syst Rev; 2013 Jul; (7):CD008201. PubMed ID: 23861035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of direct oral anticoagulants for extended duration thromboprophylaxis in medically ill patients: a systematic review and meta-analysis.
    Alshouimi RA; Al Rammah SM; Alzahrani MY; Badreldin HA; Al Yami MS; Almohammed OA
    J Thromb Thrombolysis; 2019 Oct; 48(3):422-429. PubMed ID: 31222563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct oral anticoagulants for extended-duration thromboprophylaxis in hospitalized medically ill patients: are we there yet?
    Al Yami MS; Alfayez OM; Kurdi SM; Alsheikh R
    J Thromb Thrombolysis; 2017 Jul; 44(1):1-8. PubMed ID: 28197755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of betrixaban extended prophylaxis for venous thromboembolism compared with standard-duration prophylaxis intervention in acute medically ill patients: a systematic literature review and network meta-analysis.
    Laskier V; Guy H; Fisher M; Neuman WR; Bucior I; Cohen AT; Ren S
    J Med Econ; 2019 Oct; 22(10):1063-1072. PubMed ID: 31314619
    [No Abstract]   [Full Text] [Related]  

  • 13. Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice.
    Miller KM; Brenner MJ
    Drugs; 2019 Feb; 79(3):291-302. PubMed ID: 30719631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
    Di Nisio M; Porreca E; Otten HM; Rutjes AW
    Cochrane Database Syst Rev; 2014 Aug; (8):CD008500. PubMed ID: 25171736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venous thromboembolism risk in ischemic stroke patients receiving extended-duration enoxaparin prophylaxis: results from the EXCLAIM study.
    Turpie AG; Hull RD; Schellong SM; Tapson VF; Monreal M; Samama MM; Chen M; Yusen RD;
    Stroke; 2013 Jan; 44(1):249-51. PubMed ID: 23117723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-Analysis Comparing the Efficacy, Safety, and Cost-Benefit of Direct Acting Oral Anticoagulants Versus Enoxaparin Thromboprophylaxis to Prevent Venous Thromboembolism Among Hospitalized Patients.
    Bhalla V; Abdel-Latif A; Bhalla M; Ziada K; Williams MV; Smyth SS
    Am J Cardiol; 2018 Oct; 122(7):1236-1243. PubMed ID: 30082040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended duration of thromboprophylaxis for medically ill patients: a systematic review and meta-analysis of randomised controlled trials.
    Zayed Y; Kheiri B; Barbarawi M; Banifadel M; Abdalla A; Chahine A; Obeid M; Haykal T; Yelangi A; Malapati S; Bachuwa G; Seedahmed E
    Intern Med J; 2020 Feb; 50(2):192-199. PubMed ID: 31276276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Betrixaban: A New Oral Factor Xa Inhibitor for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients.
    Garland SG; DeRemer CE; Smith SM; Gums JG
    Ann Pharmacother; 2018 Jun; 52(6):554-561. PubMed ID: 29338293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of extended duration of thromboprophylaxis for medically ill patients.
    Wang X; Chen Y; Wen D; You C; Ma L
    Eur J Intern Med; 2023 Jul; 113():22-30. PubMed ID: 37029050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative.
    Barkoudah E; Piazza G; Hecht TEH; Grant P; Deitelzweig S; Fang MC; Fanikos J; Kao CK; Barnes GD; Chen T; Ramishvili T; Schnipper JL; Goldstein JN; Ruff CT; Kaatz S; Schwartz A; Connors JM; Goldhaber SZ
    Am J Med; 2020 May; 133 Suppl 1():1-27. PubMed ID: 32362349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.